(a) |
Drugs Supported by the First Phase Programme |
The following specific self-financed cancer drugs are supported by the first phase programme:-
Item | Drug | Designated type of cancer |
Designated clinical indication |
---|---|---|---|
1 | Abiraterone# | Prostate cancer | For metastatic castration resistant prostate cancer progressed on or after docetaxel-based chemotherapy regimen |
2 | Alectinib# | Lung cancer | For the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on Crizotinib and intolerant to Ceritinib, or who have CNS-progression after Crizotinib |
3 | Axitinib# | Renal cell carcinoma | For patients with advanced renal cell carcinoma (RCC), whose disease has progressed on or after first-line treatment |
4 | Bendamustine | Leukaemia | Treatment of Chronic Lymphocytic Leukaemia (CLL) in patients who are unable to tolerate Fludarabine-based chemotherapy OR are refractory to Fludarabine |
5a | Bevacizumab | Colorectal cancer | First line treatment of RAS mutant metastatic colorectal cancer in combination with chemotherapy in patients indicated for intensive treatment OR First line treatment of RAS wild type metastatic colorectal cancer in combination with chemotherapy in patients indicated for intensive treatment who are unsuitable for or intolerant to Cetuximab / Panitumumab |
5b | Epithelial ovarian / fallopian tube / primary peritoneal cancer | With carboplatin and paclitaxel for front-line advanced epithelial ovarian / fallopian tube / primary peritoneal cancer | |
6 | Ceritinib# | Lung cancer | For adult patients with ALK-positive advanced NSCLC previously treated with Crizotinib |
7a | Enzalutamide# | Prostate cancer | For metastatic castration resistant prostate cancer progressed on or after docetaxel-based chemotherapy regimen |
7b | For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel^ | ||
8 | Everolimus# | Breast cancer | For HR+ve HER2-ve advanced breast cancer, in combination with Exemestane, in postmenopausal women with bone-only disease after recurrence or progression following a non-steroidal aromatase inhibitor |
9 | Lapatinib | Breast cancer | HER2+ve advanced breast cancer with prior therapy including an anthracycline, a taxane, and Trastuzumab |
10 | Nivolumab | Skin cancer | As monotherapy for BRAF V600 wild-type unresectable or metastatic melanoma |
11 | Obinutuzumab | Leukaemia | In combination with Chlorambucil for treatment of previously untreated chronic lymphocytic leukaemia (CLL) in adult patients with comorbidities making them unsuitable for full-dose Fludarabine or Bendamustine based therapy |
12 | Osimertinib# | Lung cancer | For the treatment of adult patients with EGFR T790M mutation-positive brain metastases from NSCLC who has progressed after previous treatment with an EGFR tyrosine kinase inhibitor |
13 | Palbociclib# | Breast cancer | For treatment of HR+ve, HER2-ve metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine based therapy in post-menopausal patients with visceral disease but not in visceral crisis |
14 | Pazopanib | Renal cell carcinoma | First line treatment for advanced renal cell carcinoma |
15 | Pegylated liposomal Doxorubicin | Ovarian cancer | Second line of platinum refractory or subsequent treatment of platinum resistant advanced ovarian cancer |
16 | Pertuzumab | Breast cancer | In combination with trastuzumab and docetaxel (taxane) in human epidermal growth factor receptor 2 protein (HER2) +ve metastatic or locally recurrent unresectable breast cancer patients with no prior anti-HER2 or chemotherapy for their metastatic disease |
17 | Ribociclib^# | Breast cancer | For treatment of HR+ve, HER2-ve metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine based therapy in post-menopausal patients with visceral disease but not in visceral crisis |
18 | Sorafenib | Liver cancer | Hepatocellular carcinoma (HCC) : ineligible for resection, transplant or loco-regional therapy |
19a | Sunitinib | Renal cell carcinoma | First line treatment for advanced renal cell carcinoma |
19b | Gastrointestinal tumour | Unresectable or metastatic gastrointestinal stromal tumour after failure or intolerance to Imatinib | |
20 | Trastuzumab | Gastric carcinoma | Combined with Cisplatin & Capecitabine or 5FU for HER2 overexpressed metastatic gastric disease (IHC2+ and confirmatory FISH+ result, or IHC3+) in treatment-naive patients for their metastatic disease |
21 | Trastuzumab emtansine (T-DM1) |
Breast cancer | As monotherapy for HER2+ve metastatic breast cancer with prior Trastuzumab and/or taxane therapy for their metastatic disease |
22 | Vemurafenib | Skin cancer | As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma |
^ | With effect from 13 July 2019. |
# | The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacy. For details, please refer to the [Information Sheet]. |
Self-financed Drugs supported by the Samaritan Fund (SF) and Community Care Fund (CCF) Medical Assistance Programme (First Phase Programme) (for specified self-financed cancer drugs)
Types of Diseases | Clinical Indications | Drugs | SF | CCF Medical Assistance Programme (1st Phase Programme) |
---|---|---|---|---|
Haematology | Acute lymphoblastic leukaemia | Dasatinib | ✓ | |
Chronic immune thrombocytopenia | Eltrombopag | ✓ | ||
Chronic lymphocytic leukaemia | Rituximab | ✓ | ||
Bendamustine, Obinutuzumab | ✓ | |||
Chronic myeloid leukaemia | Dasatinib, Nilotinib |
✓ | ||
Follicular lymphoma | Obinutuzumab^, |
✓ | ||
Mantle cell lymphoma | Ibrutinib^# | ✓ | ||
Multiple myeloma | Bortezomib, Lenalidomide |
✓ | ||
Multiple myeloma / Non-Hodgkin's lymphoma | Plerixafor | ✓ | ||
Myelodysplastic syndromes / chronic myelomonocytic leukaemia / acute myeloid leukaemia | Azacitidine | ✓ | ||
Respiratory Medicine | Idiopathic pulmonary fibrosis | Nintedanib (Ofev)^# | ✓ | |
Rheumatology | Active systemic juvenile idiopathic arthritis | Tocilizumab | ✓ | |
Ankylosing spondylitis | Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Secukinumab |
✓ | ||
Juvenile idiopathic arthritis | Adalimumab, Etanercept, Tocilizumab |
✓ | ||
Psoriatic arthritis | Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Secukinumab, Ustekinumab |
✓ |
||
Rheumatoid arthritis | Abatacept, Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Tocilizumab, Tofacitinib |
✓ | ||
Refractory rheumatoid arthritis | Rituximab | ✓ | ||
Severe, active non-life-threatening granulomatosis with polyangiitis / microscopic polyangiitis | Rituximab | ✓ | ||
Neurology | Relapsing remitting multiple sclerosis | Alemtuzumab, Natalizumab |
✓ | |
Oncology | Breast cancer | Trastuzumab | ✓ | |
Everolimus#, Lapatinib, Palbociclib#, Pertuzumab, Ribociclib^#, Trastuzumab emtansine |
✓ | |||
Colorectal cancer | Cetuximab, Panitumumab |
✓ | ||
Bevacizumab | ✓ | |||
Gastric carcinoma | Trastuzumab | ✓ | ||
Gastrointestinal tumour | Sunitinib | ✓ | ||
Gastrointestinal stromal tumour | Imatinib | ✓ | ||
Recurrent high grade glioma | Temozolomide | ✓ | ||
Liver cancer | Sorafenib | ✓ | ||
Lung cancer | Ceritinib*#, | ✓^ | ✓ | |
Afatinib**, Crizotinib#, Erlotinib~, Gefitinib~ |
✓ | |||
Alectinib#, Osimertinib# |
✓ | |||
Malignant lymphoma | Rituximab | ✓ | ||
Ovarian cancer | Pegylated liposomal Doxorubicin | ✓ | ||
Epithelial ovarian / fallopian tube / primary peritoneal cancer |
Bevacizumab | ✓ | ||
Prostate cancer | Abiraterone#, Enzalutamide# |
✓ | ||
Renal cell carcinoma | Axitinib#, Sunitinib, Pazopanib |
✓ | ||
Skin cancer | Nivolumab, Vemurafenib |
✓ | ||
Gastroenterology | Severe ulcerative colitis | Infliximab, Vedolizumab |
✓ | |
Ophthalmology | Non-infectious intermediate, posterior and panuveitis | Adalimumab | ✓ | |
Endocrinology | Dwarfism | Growth Hormone | ✓ | |
Dermatology | Severe psoriasis | Adalimumab, Etanercept, Infliximab, Secukinumab, Ustekinumab |
✓ | |
Others | Chronic granulomatous disease | Interferon | ✓ | |
Cryopyrin-associated periodic syndromes | Canakinumab | ✓ |
Remarks:
^ | With effect from 13 July 2019. |
* | The designated clinical indications of the same drug supported by different funds are different. Please consult your case doctor for details. |
** | Afatinib is for first-line treatment for patients with activating EGFR mutation positive non-small cell lung cancer. The drug/indication was repositioned from CCF Medical Assistance Programme (First Phase Programme) to SF with effect from 16 February 2019. New applications and renewal applications approved on or after the effective date were subsidized by SF. For applications already approved before the effective date, CCF subsidy were provided until end of treatment of the applications. |
~ | Erlotinib and Gefitinib are for first-line and second-line treatment for patients with activating EGFR mutation positive non-small cell lung cancer. First-line treatment was repositioned from CCF Medical Assistance Programme (First Phase Programme) to SF with effect from 16 February 2019. New applications and renewal applications approved on or after the effective date were subsidized by SF. For applications already approved before the effective date, CCF subsidy were provided until end of treatment of the applications. |
# | The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacy. For details, please refer to the [Information Sheet]. |
(b) |
Drugs Supported by the Programme “Subsidy for Eligible Patients to Purchase Ultra-expensive Drugs (Including Those for Treating Uncommon Disorders)” |
Item | Drug | Designated clinical indication |
---|---|---|
1a | Eculizumab | Paroxysmal Nocturnal Haemoglobinuria |
1b | Atypical haemolytic uraemic syndrome | |
2 | Nusinersen | Infantile Onset Spinal Muscular Atrophy (SMA) / Childhood Onset Spinal Muscular Atrophy (SMA) |
3 | Tafamidis | For the treatment of transthyretin amyloidosis in adult patients |
(c) |
Implantable Medical Devices Supported by the Programme “Subsidy for Eligible Patients of Hospital Authority to Purchase Specified Implantable Medical Devices for Interventional Procedures” |